News for Ascentage Pharma Group International (ASPHF)

Summary Ascentage Pharma Group International (AAPG), a global biopharmaceutical company, announced on June 9, 2025, that it will present 13 studies at the 2025

Summary Ascentage Pharma Group International (AAPG) has announced the release of new clinical data from its Phase II study of the MDM2-p53 inhibitor alrizomadli

Summary Ascentage Pharma Group International (AAPG), a global biopharmaceutical company, announced on May 22, 2025, that it will present new clinical data from

Summary Ascentage Pharma Group International (AAPG), a global biopharmaceutical company, announced on April 23, 2025, that two of its clinical studies have been

**media[578221]**

Discover Ascentage Pharma's FY results: GAAP EPS of -$0.18, revenue reaching $134.3M. Explore key financial insights and performance highlights.

Ascentage Pharma Group International (AAPG), a global biopharmaceutical company, announced on February 7, 2025, that the underwriters of its U.S. initial public

Ascentage Pharma shares slide ahead of ADS debut on Nasdaq

ROCKVILLE, Md. and SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that its Chairman and CEO, Dr. Dajun Yang, has accepted an invitation to present on the company's progress and prospects under its patient-centric global innovation strategy, at 1:15 PM, January 16, 2025, Pacific Time (5:15 AM, January 17, 2025, Beijing Time) at the 43rd Annual J.P. Morgan Healthcare Conference.

Key Takeaways: Under the partnership, Japan’s Takeda International gets an option to market Ascentage’s promising leukemia drug outside of China Without the capital infusion from Takeda, Ascentage was facing a liquidity crisis with just a year’s worth of cash By Molly Wen

SUZHOU, China and ROCKVILLE, Md., Jan. 1, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...

Over a dozen Chinese-based firms say they have minimal exposure to SVB

HONG KONG — Over a dozen Hong Kong-listed companies have stepped forward to say they had little or no exposure to Silicon Valley Bank, the failed U.S. lender…

Six Hong Kong-listed firms say their deposits at SVB are immaterial

Six Hong Kong-listed companies, mostly Chinese pharmaceutical firms, disclosed cash deposits at Silicon Valley Bank on Sunday, adding that their exposure to the failed U.S. lender and its impact... | March 12, 2023